Clinical Trial Update: Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia [Phase 3]

View source ↗

Summary

Phase 3 trial in Chinese participants evaluating evolocumab added to background statin therapy for primary hypercholesterolemia and mixed dyslipidemia; study te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Amgen | Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Status: TERMINATED | Results posted: 2021-08-20